Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy Expected in mid-2024, a Global...
Joyce Allaire Sheryl Seapy International Guillain Barr Securities Exchange Clinical Program Updates European Medicines Agency
Source: marketscreener.com